Related Experiment Videos
[Gene therapy for adenosine deaminase deficiency]
1Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan.
[Hokkaido Igaku Zasshi] the Hokkaido Journal of Medical Science
|January 1, 1996
Summary
Gene therapy successfully treated a boy with adenosine deaminase (ADA) deficiency, a severe combined immunodeficiency (SCID). This study details the procedure, safety, and efficacy of using a retroviral vector for ADA gene transfer in T lymphocytes.
Area of Science:
- Immunology
- Genetics
- Biotechnology
Context:
- Adenosine deaminase (ADA) deficiency causes severe combined immunodeficiency (SCID), a fatal genetic disorder.
- Previous gene therapy trials demonstrated potential for treating ADA-SCID.
Purpose:
- To conduct a clinical trial for a boy with ADA-deficient SCID using gene therapy.
- To evaluate the safety and efficacy of ADA gene transfer into T lymphocytes via a retroviral vector (LASN).
Summary:
- A four-year-old boy with ADA-deficient SCID received intravenous infusions of LASN-transduced T lymphocytes.
- The gene therapy procedure involved transferring the ADA gene using a recombinant retroviral vector.
- The patient experienced no adverse reactions during the treatment period.
Impact:
- This study provides crucial data on the safety and efficacy of gene therapy for ADA-deficient SCID.
- The findings contribute to the advancement of genetic medicine and treatment strategies for primary immunodeficiencies.